Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment.
Frank Xiaoqing Liu, Edward A Witt, Scot Ebbinghaus and 3 others
PMID 29076867WHAT IT FOUND
Patients and oncology nurses ranked treatment features similarly.
Both ranked overall survival, serious adverse events, and response rate above dosing, administration, and duration.
Key findings
01Patients rated overall survival, serious adverse events, and objective response rate as the most important attributes, with progression-free survival less important.
02Oncology nurses rated overall survival, objective response rate, and serious adverse events as the most important attributes.
03The difference between patient and nurse rankings was not statistically significant.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The choices were hypothetical, so they may not match how patients and nurses weigh real treatment decisions. The patients were recruited online and were younger, healthier, and more likely to be employed than the broader US advanced melanoma population. The nurses came from an online panel, so they may not represent all US oncology nurses. The study was funded by a manufacturer of melanoma medication.
Declared interests
Merck & Co funded the study and employs authors; Kantar Health received funding from Merck to conduct it; an author served as a paid consultant for Merck.
The easy way to misread this
Do not read this as evidence that any treatment works or that convenience attributes can be ignored. It measured hypothetical preferences, and some patients directly ranked dosing, administration, or duration among their most important choices.